AEON Biopharma, Inc.
AEON
$0.40
-$0.0093-2.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -43.87% | -51.84% | -32.85% | 21.04% | -14.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.90% | -71.88% | -44.46% | -20.43% | -23.24% |
| Operating Income | 50.90% | 71.88% | 44.46% | 20.43% | 23.24% |
| Income Before Tax | 107.93% | 98.10% | 1,167.12% | -569.07% | 24.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 107.93% | 98.10% | 1,167.12% | -569.07% | 24.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 107.93% | 98.10% | 1,167.12% | -569.07% | 24.07% |
| EBIT | 50.90% | 71.88% | 44.46% | 20.43% | 23.24% |
| EBITDA | 50.99% | 72.00% | 44.54% | 20.47% | 23.24% |
| EPS Basic | 107.39% | 97.10% | 3,913.84% | -2,392.35% | -183.71% |
| Normalized Basic EPS | -44.64% | 83.63% | 127.82% | -1,454.12% | 23.34% |
| EPS Diluted | 106.82% | 97.03% | 3,913.84% | -2,392.35% | -183.71% |
| Normalized Diluted EPS | -44.36% | 83.63% | 127.82% | -1,454.12% | 23.34% |
| Average Basic Shares Outstanding | 7.40% | -34.55% | -72.02% | -73.15% | -73.24% |
| Average Diluted Shares Outstanding | 7.60% | -34.55% | -72.02% | -73.15% | -73.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
